<DOC>
	<DOCNO>NCT01481259</DOCNO>
	<brief_summary>Maintenance therapy consider important component prolong survival patient advance Nonsquamous Non-small Cell Lung Cancer ( NSCLC ) . Previous study confirm pemetrexed one effective drug improve progression-free survival stage IIIb-IV nonsquamous non-small cell lung cancer . With periodic delivery pemetrexed , however , function status immune system may get bad , subsequently negative impact patient 's quality-of-life . Immunotherapy autologous cytokine-induced killer ( CIK ) cell activate antitumor defense mechanism stimulate immune response alter interaction tumor host . This effect may result improved tumor control survival , well good quality life . To test hypothesis , randomise control study conduct compare CIK cell pemetrexed maintenance therapy stage IIIb-IV nonsquamous non-small cell lung cancer .</brief_summary>
	<brief_title>Maintenance Therapy With Autologous Cytokine-induced Killer Cells Nonsquamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically proven nonsquamous nonsmall cell lung cancer Stage IIIbIV , accord AJCC 2010 Staging System Disease measurable Patients currently receive twodrug chemotherapy regimen contain platinumbased drug firstline therapy No chemotherapy radiotherapy prior firstline therapy Age 1875 Performance status ï¼œ2 No congestive heart failure , severe arrhythmia , coronal atherosclerosis heart disease No uncontrolled metabolic disease , infection , neurological disorder No malignancy Signed studyspecific consent form prior study entry Patients currently receive radiotherapy chemotherapy regimen twodrug contain platinumbased drug firstline therapy Pregnant lactate woman Patient hepatitis B virus infection , active tuberculosis , infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Nonsquamous non-small cell lung cancer</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Autologous cytokine-induced killer cell</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>